FI2291080T5 - Uusia sfingosiinifosfaattireseptorimodulaattoreita - Google Patents
Uusia sfingosiinifosfaattireseptorimodulaattoreita Download PDFInfo
- Publication number
- FI2291080T5 FI2291080T5 FIEP09762826.7T FI09762826T FI2291080T5 FI 2291080 T5 FI2291080 T5 FI 2291080T5 FI 09762826 T FI09762826 T FI 09762826T FI 2291080 T5 FI2291080 T5 FI 2291080T5
- Authority
- FI
- Finland
- Prior art keywords
- compound
- compound according
- phosphate receptors
- novel modulators
- sphingosine phosphate
- Prior art date
Links
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12760308P | 2008-05-14 | 2008-05-14 | |
| PCT/US2009/003014 WO2009151529A1 (en) | 2008-05-14 | 2009-05-14 | Novel modulators of sphingosine phosphate receptors |
| US12/465,767 US8796318B2 (en) | 2008-05-14 | 2009-05-14 | Modulators of sphingosine phosphate receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI2291080T3 FI2291080T3 (enExample) | 2015-10-15 |
| FI2291080T5 true FI2291080T5 (fi) | 2023-11-06 |
Family
ID=41416994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP09762826.7T FI2291080T5 (fi) | 2008-05-14 | 2009-05-14 | Uusia sfingosiinifosfaattireseptorimodulaattoreita |
| FIC20200037C FIC20200037I1 (fi) | 2008-05-14 | 2020-09-24 | Otsanimodi tai sen farmaseuttisesti hyväksyttävä suola, erityisesti otsanimodihydrokloridi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIC20200037C FIC20200037I1 (fi) | 2008-05-14 | 2020-09-24 | Otsanimodi tai sen farmaseuttisesti hyväksyttävä suola, erityisesti otsanimodihydrokloridi |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US8796318B2 (enExample) |
| EP (3) | EP2913326B1 (enExample) |
| JP (2) | JP5837417B2 (enExample) |
| AU (2) | AU2009258242B2 (enExample) |
| CY (2) | CY1123338T1 (enExample) |
| DK (1) | DK2291080T3 (enExample) |
| EA (1) | EA021672B1 (enExample) |
| ES (2) | ES2549761T3 (enExample) |
| FI (2) | FI2291080T5 (enExample) |
| HR (1) | HRP20150982T1 (enExample) |
| HU (2) | HUE025984T2 (enExample) |
| LT (1) | LTC2291080I2 (enExample) |
| MY (2) | MY156381A (enExample) |
| NL (1) | NL301065I2 (enExample) |
| NO (1) | NO2020034I1 (enExample) |
| NZ (1) | NZ589617A (enExample) |
| PL (2) | PL2291080T3 (enExample) |
| PT (2) | PT2291080E (enExample) |
| SI (1) | SI2291080T1 (enExample) |
| WO (1) | WO2009151529A1 (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2069336T3 (pl) | 2006-09-07 | 2013-05-31 | Idorsia Pharmaceuticals Ltd | Pochodne pirydyn-4-ylu jako środki immunomodulujące |
| SI2125797T1 (sl) | 2007-03-16 | 2014-03-31 | Actelion Pharmaceuticals Ltd. | Derivati amino-piridina kot agonisti receptorja s1p1/edg1 |
| ES2361463T3 (es) | 2007-08-17 | 2011-06-17 | Actelion Pharmaceuticals Ltd. | Derivados de piridina como moduladores del receptor s1p1/edg1. |
| EP2217594B1 (en) | 2007-11-01 | 2014-01-08 | Actelion Pharmaceuticals Ltd. | Novel pyrimidine derivatives |
| MX2010005889A (es) | 2007-12-10 | 2010-06-22 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno como agonistas de s1p1/edg1. |
| CA2715317A1 (en) | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
| EP2913326B1 (en) | 2008-05-14 | 2020-07-15 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| ES2714453T3 (es) * | 2008-06-09 | 2019-05-28 | Univ Muenchen Ludwig Maximilians | Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas |
| AR072184A1 (es) * | 2008-06-20 | 2010-08-11 | Glaxo Group Ltd | Derivados de oxadiazol como agonistas del receptor s1p1 |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| EP2342205B1 (en) | 2008-08-27 | 2016-04-20 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| JP2012515788A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置における、ｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| WO2010085581A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| WO2011007324A1 (en) | 2009-07-16 | 2011-01-20 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| HUE037535T2 (hu) * | 2009-11-13 | 2018-09-28 | Celgene Int Ii Sarl | Szelektív szfingozin-1-foszfát receptor modulátorok és királis szintézis eljárások |
| CN105130922A (zh) * | 2009-11-13 | 2015-12-09 | 瑞塞普托斯公司 | 选择性的杂环1-磷酸鞘氨醇受体调节剂 |
| BR112012011430A8 (pt) * | 2009-11-13 | 2017-12-26 | Celgene Int Ii Sarl | Compostos moduladores de receptor de esfingosina 1 fosfato e composições farmacêuticas |
| AU2015202660B2 (en) * | 2009-11-13 | 2016-10-27 | Receptos Llc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
| ES2558087T3 (es) | 2010-03-03 | 2016-02-01 | Arena Pharmaceuticals, Inc. | Procesos para la preparación de moduladores del receptor S1P1 y formas cristalinas de los mismos |
| EP2390252A1 (en) * | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| US9187437B2 (en) * | 2010-09-24 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds |
| UA109804C2 (xx) | 2011-01-19 | 2015-10-12 | 2-метоксипіридин-4-ільні похідні | |
| WO2012118935A1 (en) | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
| CN102718726A (zh) * | 2011-03-31 | 2012-10-10 | 上海铂力生物科技有限公司 | 作为免疫调节剂的(z)-5-苯亚甲基噻唑啉-4-酮衍生物 |
| ES2758841T3 (es) * | 2011-05-13 | 2020-05-06 | Celgene Int Ii Sarl | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| EP2822931B1 (en) | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| JP6404230B2 (ja) | 2012-12-20 | 2018-10-10 | インセプション ２、 インコーポレイテッド | トリアゾロン化合物およびその使用 |
| EP2958913B1 (en) | 2013-02-20 | 2018-10-03 | LG Chem, Ltd. | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| JP6387361B2 (ja) * | 2013-03-15 | 2018-09-05 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ピリジン−４−イル誘導体 |
| CA2921420A1 (en) | 2013-09-06 | 2015-03-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| EP2853532B1 (en) * | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
| WO2015066515A1 (en) * | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| US9828351B2 (en) * | 2014-06-26 | 2017-11-28 | Monash University | Enzyme interacting agents |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| WO2016164180A1 (en) | 2015-04-06 | 2016-10-13 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
| MY192358A (en) | 2015-05-20 | 2022-08-17 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
| CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
| CN109219597A (zh) | 2016-06-14 | 2019-01-15 | 苏州科睿思制药有限公司 | 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法 |
| US11028060B2 (en) | 2016-08-19 | 2021-06-08 | Receptos Llc | Crystalline forms of ozanimod and processes for preparation thereof |
| EP3508481A1 (en) | 2016-09-14 | 2019-07-10 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of ozanimod hydrochloride, and preparation method therefor |
| KR102408814B1 (ko) | 2016-09-29 | 2022-06-14 | 리셉토스 엘엘씨 | 루푸스를 치료하기 위한 화합물 및 방법 |
| CA3051095A1 (en) | 2017-01-23 | 2018-07-26 | Naqi Logics, Llc | Apparatus, methods, and systems for using imagined direction to define actions, functions, or execution |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| JP7123956B2 (ja) * | 2017-02-28 | 2022-08-23 | ヘリオイースト・ファーマシューティカル・カンパニー・リミテッド | スピロ化合物およびその使用 |
| US20210163485A1 (en) * | 2017-05-17 | 2021-06-03 | Oppilan Pharma Ltd. | Heterocyclic Compounds for the Treatment of Disease |
| EP3677575A4 (en) | 2017-08-31 | 2020-07-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
| WO2020152718A1 (en) | 2019-01-25 | 2020-07-30 | Mylan Laboratories Limited | Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile |
| JP2022529845A (ja) * | 2019-04-26 | 2022-06-24 | レセプトス・リミテッド・ライアビリティ・カンパニー | スフィンゴシン１リン酸受容体調節因子 |
| CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
| WO2021026479A1 (en) * | 2019-08-07 | 2021-02-11 | Stamford, Andrew | Small molecule inhibitors of s1p2 receptor and uses thereof |
| AU2020407664A1 (en) | 2019-12-20 | 2022-08-18 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| WO2021195413A1 (en) * | 2020-03-27 | 2021-09-30 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| WO2021195397A1 (en) * | 2020-03-27 | 2021-09-30 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| JP7653447B2 (ja) * | 2020-03-27 | 2025-03-28 | レセプトス・リミテッド・ライアビリティ・カンパニー | スフィンゴシン１ホスフェート受容体モジュレーター |
| WO2021207051A1 (en) * | 2020-04-06 | 2021-10-14 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
| US20230233532A1 (en) * | 2020-06-26 | 2023-07-27 | The Penn State Research Foundation | Sphingosine-1-phosphate receptor 1 agonist and liposomal formulations thereof |
| CA3191164A1 (en) * | 2020-08-10 | 2022-02-17 | Dana-Farber Cancer Institute, Inc. | Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28 |
| EP4333841A1 (en) | 2021-05-04 | 2024-03-13 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
| JP7478894B1 (ja) | 2022-11-30 | 2024-05-07 | 花王株式会社 | 痒みの予防又は改善剤 |
| WO2024246174A1 (en) | 2023-05-31 | 2024-12-05 | Química Sintética, S.A. | Amorphous and crystalline form of ozanimod hydrochloride |
| CN119320366B (zh) * | 2023-07-17 | 2025-11-18 | 中国医学科学院药物研究所 | 取代萘甲基噁二唑-苯胺类化合物及其用途 |
| US11905265B1 (en) * | 2023-10-13 | 2024-02-20 | King Faisal University | 3,4-dimethoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| TR200002072T2 (tr) | 1998-01-23 | 2000-12-21 | Sankyo Company Limited | Spiropiperidin türevleri |
| DE10240818A1 (de) | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| CA2509218C (en) * | 2002-12-20 | 2010-09-07 | Merck & Co., Inc. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists |
| WO2004096220A1 (en) | 2003-04-30 | 2004-11-11 | Merck Frosst Canada Ltd. | 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors |
| WO2004110351A2 (en) * | 2003-05-14 | 2004-12-23 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis c virus |
| AU2004277947A1 (en) * | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
| AU2004299456B2 (en) | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| WO2005058845A2 (en) * | 2003-12-19 | 2005-06-30 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| PT1650186E (pt) * | 2004-10-22 | 2008-09-16 | Bioprojet Soc Civ | Novos derivados de ácidos dicarboxílicos |
| EP1851188A1 (en) | 2005-02-22 | 2007-11-07 | Teva Pharmaceutical Industries Limited | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| WO2006131336A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| ES2375929T3 (es) | 2005-07-04 | 2012-03-07 | High Point Pharmaceuticals, Llc | Antagonistas del receptor histamina h3. |
| AU2006328602B2 (en) | 2005-12-23 | 2012-05-31 | F. Hoffmann-La Roche Ag | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
| JP5099005B2 (ja) | 2006-04-03 | 2012-12-12 | アステラス製薬株式会社 | ヘテロ化合物 |
| US20080015193A1 (en) | 2006-06-20 | 2008-01-17 | Mendoza Jose S | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof |
| US20080009534A1 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| CN101522646A (zh) | 2006-09-29 | 2009-09-02 | 诺瓦提斯公司 | 具有抗炎和免疫抑制特性的二唑衍生物 |
| EP2099741A2 (en) * | 2006-11-21 | 2009-09-16 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| MX2009006304A (es) | 2006-12-15 | 2009-06-23 | Abbott Lab | Nuevos compuestos de oxadiazol. |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| US20090188269A1 (en) | 2008-01-25 | 2009-07-30 | Henkel Corporation | High pressure connection systems and methods for their manufacture |
| EP2913326B1 (en) | 2008-05-14 | 2020-07-15 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| DK2913326T3 (da) | 2008-05-14 | 2020-08-17 | Scripps Research Inst | Hidtil ukendte modulatorer af sphingosinphosphatreceptorer |
-
2009
- 2009-05-14 EP EP15158887.8A patent/EP2913326B1/en active Active
- 2009-05-14 EP EP09762826.7A patent/EP2291080B1/en active Active
- 2009-05-14 PT PT97628267T patent/PT2291080E/pt unknown
- 2009-05-14 AU AU2009258242A patent/AU2009258242B2/en active Active
- 2009-05-14 PL PL09762826T patent/PL2291080T3/pl unknown
- 2009-05-14 EP EP20185750.5A patent/EP3782991A1/en not_active Withdrawn
- 2009-05-14 EA EA201001785A patent/EA021672B1/ru unknown
- 2009-05-14 MY MYPI2010005338A patent/MY156381A/en unknown
- 2009-05-14 PL PL15158887T patent/PL2913326T3/pl unknown
- 2009-05-14 NZ NZ589617A patent/NZ589617A/en unknown
- 2009-05-14 FI FIEP09762826.7T patent/FI2291080T5/fi active
- 2009-05-14 DK DK09762826.7T patent/DK2291080T3/en active
- 2009-05-14 PT PT151588878T patent/PT2913326T/pt unknown
- 2009-05-14 US US12/465,767 patent/US8796318B2/en active Active
- 2009-05-14 HU HUE09762826A patent/HUE025984T2/hu unknown
- 2009-05-14 HR HRP20150982TT patent/HRP20150982T1/hr unknown
- 2009-05-14 JP JP2011509488A patent/JP5837417B2/ja active Active
- 2009-05-14 MY MYPI2015000801A patent/MY172105A/en unknown
- 2009-05-14 ES ES09762826.7T patent/ES2549761T3/es active Active
- 2009-05-14 ES ES15158887T patent/ES2813368T3/es active Active
- 2009-05-14 WO PCT/US2009/003014 patent/WO2009151529A1/en not_active Ceased
- 2009-05-14 SI SI200931271T patent/SI2291080T1/sl unknown
-
2012
- 2012-09-06 US US13/605,427 patent/US8466183B2/en active Active
- 2012-09-06 US US13/605,358 patent/US8530503B2/en active Active
- 2012-09-06 US US13/605,561 patent/US8481573B2/en active Active
-
2014
- 2014-06-23 US US14/311,825 patent/US9382217B2/en active Active
-
2015
- 2015-08-12 AU AU2015213309A patent/AU2015213309B2/en active Active
- 2015-11-05 JP JP2015217236A patent/JP2016041736A/ja active Pending
-
2016
- 2016-06-21 US US15/188,132 patent/US20170050941A1/en not_active Abandoned
-
2017
- 2017-09-22 US US15/713,237 patent/US9975863B2/en active Active
-
2018
- 2018-04-23 US US15/959,935 patent/US10544136B2/en active Active
-
2020
- 2020-09-11 CY CY20201100862T patent/CY1123338T1/el unknown
- 2020-09-24 FI FIC20200037C patent/FIC20200037I1/fi unknown
- 2020-09-29 NO NO2020034C patent/NO2020034I1/no unknown
- 2020-09-30 NL NL301065C patent/NL301065I2/nl unknown
- 2020-10-01 LT LTPA2020529C patent/LTC2291080I2/lt unknown
- 2020-10-01 HU HUS2000038C patent/HUS2000038I1/hu unknown
- 2020-10-02 CY CY2020033C patent/CY2020033I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI2291080T5 (fi) | Uusia sfingosiinifosfaattireseptorimodulaattoreita | |
| FI2049506T4 (fi) | Lääkkeellisten aineiden farmakokineettisten ominaisuuksien modulaattorit | |
| CL2008000127A1 (es) | Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos | |
| CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
| CL2009000815A1 (es) | Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria. | |
| WO2018042362A9 (en) | Muscarinic m1 receptor positive allosteric modulators | |
| EA201291220A1 (ru) | Производные аминопиримидина в качестве модуляторов lrrk2 | |
| CL2008000946A1 (es) | Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun | |
| SI2820009T1 (en) | Serine / Threonine kinase inhibitors | |
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| JP2006298933A5 (enExample) | ||
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| MX2014006026A (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). | |
| MX348920B (es) | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
| CL2013001885A1 (es) | Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08). | |
| MX348606B (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2). | |
| IL217052A0 (en) | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them | |
| NO20082180A (no) | Fremgangsmåte for fremstilling av en Faktor IX formulering for intravenøs injeksjon | |
| EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
| BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
| BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" | |
| MX2010009395A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos. | |
| EP2355862A4 (en) | TWO-CHAMBER MEDICAL DISPLAY DEVICE FOR HIGH PRESSURE INJECTIONS | |
| CL2007000680A1 (es) | Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc. | |
| MX2012001160A (es) | Agonistas del receptor de esfingosina-1-fosfato. |